Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Compugen Ltd (CGEN)

Compugen Ltd (CGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 287,241
  • Shares Outstanding, K 51,293
  • Annual Sales, $ 17,800 K
  • Annual Income, $ -22,600 K
  • 60-Month Beta 2.73
  • Price/Sales 16.71
  • Price/Cash Flow N/A
  • Price/Book 7.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.11
  • Number of Estimates 2
  • High Estimate -0.10
  • Low Estimate -0.12
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +31.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.20 +8.65%
on 12/04/19
6.13 -7.83%
on 12/02/19
+0.14 (+2.54%)
since 11/13/19
3-Month
3.83 +47.61%
on 10/18/19
6.22 -9.16%
on 11/06/19
+1.42 (+33.57%)
since 09/13/19
52-Week
2.00 +182.50%
on 12/31/18
6.22 -9.16%
on 11/06/19
+2.50 (+79.37%)
since 12/13/18

Most Recent Stories

More News
Janpix, Inc. Announces Appointment of Sanford (Sandy) Zweifach as Executive Chairman to its Board of Directors

-Addition of Experienced Executive to Leadership Team-

CGEN : 5.65 (+0.89%)
EPIX : 6.00 (+2.39%)
The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech

The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech

CGEN : 5.65 (+0.89%)
EPZM : 17.71 (-0.56%)
ACAD : 44.34 (-0.40%)
CUE : 13.56 (+9.35%)
KRYS : 65.23 (+1.56%)
5 Biotech Stocks Up More Than 100% This Year So Far

The biotech sector recovers on the back of rising M&A activities and pipeline successes in 2019 after a dismal 2018. Here we discuss five biotech companies recording impressive growth.

EPZM : 17.71 (-0.56%)
CGEN : 5.65 (+0.89%)
ACAD : 44.34 (-0.40%)
KRYS : 65.23 (+1.56%)
CUE : 13.56 (+9.35%)
Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice

Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

CGEN : 5.65 (+0.89%)
FoxWise Technologies Inc. and Compugen Inc. Announce a Strategic Investment by Compugen in FoxWise

Today, FoxWise Technologies Inc., one of Canada's premiere Indigenous IT firms, and Compugen Inc., a Richmond Hill, Ontario based IT solution provider, are pleased to announce a strategic investment by...

CGEN : 5.65 (+0.89%)
Compugen Reports Third Quarter 2019 Results

Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the third quarter ended September 30, 2019....

CGEN : 5.65 (+0.89%)
Compugen Expands Patent Portfolio for COM902 with New Composition of Matter and Use Patent in Europe

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that The European Patent Office (EPO) has granted a new patent covering...

CGEN : 5.65 (+0.89%)
Compugen Presents Preclinical Data for COM902 Anti-TIGIT Program at SITC 2019

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today disclosed preclinical results from its COM902 anti-TIGIT program supporting...

CGEN : 5.65 (+0.89%)
Compugen Presents Initial Clinical Data from Ongoing Phase 1 Trial of COM701 in Patients with Advanced Solid Tumors at SITC 2019

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today disclosed preliminary results from its ongoing Phase 1 dose escalation study...

CGEN : 5.65 (+0.89%)
Compugen Announces FDA Clearance of IND Application for COM902

Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U.S. Food and Drug Administration has cleared its investigational...

CGEN : 5.65 (+0.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CGEN with:

Business Summary

Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen's expertise in these areas...

See More

Key Turning Points

2nd Resistance Point 5.80
1st Resistance Point 5.72
Last Price 5.65
1st Support Level 5.54
2nd Support Level 5.44

See More

52-Week High 6.22
Last Price 5.65
Fibonacci 61.8% 4.61
Fibonacci 50% 4.11
Fibonacci 38.2% 3.61
52-Week Low 2.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar